These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37292114)

  • 1. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Jiang J; Zhang H; Lai J; Zhang S; Ou Y; Fu Y; Zhang L
    J Hepatocell Carcinoma; 2024; 11():1607-1622. PubMed ID: 39206422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Wu JY; Yin ZY; Bai YN; Chen YF; Zhou SQ; Wang SJ; Zhou JY; Li YN; Qiu FN; Li B; Yan ML
    J Hepatocell Carcinoma; 2021; 8():1233-1240. PubMed ID: 34676181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B; Dai H; Yang J; Zhang G; Wen C; Xiang X; Lin R; Huang Y
    Curr Cancer Drug Targets; 2023; 23(7):564-571. PubMed ID: 36790005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; 110(12):7860-70. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
    Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
    Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study.
    Shen C; Jiang W; Chen R; Li L; Wu Y; Tan L; Chen Y; Zhang W; Wang Z
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):427. PubMed ID: 39302490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
    Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
    Front Oncol; 2022; 12():982948. PubMed ID: 36172158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C
    Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
    Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
    J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
    [No Abstract]   [Full Text] [Related]  

  • 17. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
    Teng Y; Ding X; Li W; Sun W; Chen J
    Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
    [No Abstract]   [Full Text] [Related]  

  • 18. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
    Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
    Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.
    Schindler P; Kaldewey D; Rennebaum F; Trebicka J; Pascher A; Wildgruber M; Köhler M; Masthoff M
    J Cancer Res Clin Oncol; 2024 May; 150(5):235. PubMed ID: 38710956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.